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ABSTRACT 
Objective: The objective of present study was to develop effervescent tablets of Chlorpheniramine maleate (CPM) for the treatment of dysphasia. 
Methods: Effervescent tablets were prepared by direct compression method and were optimized using box behnken design. Amount to sodium 
bicarbonate (X1), amount of tartaric acid (X2) and amount of fumaric acid (X3) were selected as independent variables, whereas disintegration time 
(Y1), amount of carbon dioxide (Y2) and drug release in 5 minutes (Y3
Results: The disintegration time ranged from 103.33 ± 0.24 sec to 157.00 ± 0.75 sec while amount of carbon dioxide ranged from 0.26±0.014 g to 
2.03±0.056 g in all the design batches. From the results of design batches, batch B4 was selected as optimized batch due to higher amount of 
released carbon dioxide and faster drug release as compared to other batches. Batch B4 was showing higher AUC and C
) were selected as dependent variables. All the batches were also evaluated 
for general post compression evaluation of tablet such as-weight variation, thickness, friability and hardness. From the results of design batches, 
best batch was selected and evaluated for in vivo pharmacokinetic study in rabbit model. 
max while lower tmax
Conclusion: The study concluded that the combination of sodium bicarbonate, tartaric acid and fumaric acid approach for development of 
effervescent tablet aids to achieve faster disintegration and faster drug release property for CPM. 
 as 
compared to drug suspension while performing in vivo study of optimized batch in rabbit model. 
Keywords: Effervescent tablet, Chlorpheniramine maleate, Dysphasia,
 
 Optimization, Box behnken design. 
INTRODUCTION 
In dysphagia, patient exhibits a problem in the throat or esophagus 
which causes difficulty in swallowing. In such condition, food moves 
back to mouth from the stomach by the muscular tube. Dysphagia 
can be of two types: oropharyngeal and esophageal. The problem in 
vacating material into the esophagus from oropharynx is known as 
oropharyngeal dysphagia. While, problem of passing food 
downward to the esophagus is known as esophageal dysphagia. 
Although this disease can be happening to any age of people but 
found commonly in elderly patient and children. In normal 
condition, due to throat and esophagus muscles contraction, food 
can easily move to the stomach. In dysphagia, muscles and nerves 
which help in movement of food toward stomach could not work 
properly which may be due to the injury in brain, problem in 
nervous system, esophageal spasm, inflammation in esophagus etc. 
Sometimes less quantity of saliva in mouth can also decrease the 
food movement to stomach. In such condition, only liquid or few 
solid dosage forms, which can be easily converted into a solution or 
suspension, are helpful for the treatment. Effervescent tablet is one 
of the best suitable dosage forms for such type of drugs 
Effervescence is described as an expulsion of carbon dioxide gas 
from a fluid due to chemical reaction. This effect starts when 
formulation come in contact with water which works as catalyzing 
agent. Effervescent tablets need to be dissolved in water before 
administration. The tablet is promptly broken down by releasing 
carbon dioxide in water. Carbon dioxide produces by effervescent 
reaction increases the penetration of active substance into the 
paracellular pathway and consequently their absorption. The 
effervescent formulation are administered in form of solution, hence 
it does not come in direct contact with the gastrointestinal tract 
which makes such dosage forms useful for this kind of patient [3]. 
[1, 2].  
H1 antagonists are used for the treatment of allergenic disorders, 
prurities, common cold, cough, motion sickness, vertigo etc. 
Parenteral H1 antagonists are used for effective control of violent 
vertigo, vomiting and acute muscle dystopia. Quick relief can be 
achieved by administering oral effervescent formulation of H1 
antagonist in above mentioned conditions and thus helps in avoiding 
the invasive route for such conditions. Chlorpheniramine maleate 
(CPM) is a first-generation alkylamine antihistamine, used in the 
treatment of allergic condition such as rhinitis, urticarial and hay 
fever. CPM blocks certain natural histamine that body secretes 
during allergic reaction and acetylcholine [4, 5]. Dysphagia caused 
by allergic reactions and lower amount of saliva can be treated by 
administering CPM effervescent formulation.  
Production of effervescent formulation requires higher environmental 
control with respect to atmospheric moisture. The ingredients, acid and 
carbonate or bicarbonate sources, used are very sensitive to moisture. In 
presence of moisture, this combination may lead to a reaction and make 
the product unstable [6-8]. Preliminary studies were conducted to 
evaluate different acid sources and the results indicated that the tartaric 
and fumaric acid is less hygroscopic as compared to citric acid. 
Development of the effervescent tablets in the present study did not 
require complicated technology/instruments or specific atmospheric 
conditions, which ultimately trim down the product cost. The objective 
of the present study was to prepare and evaluate an effervescent 
formulation of CPM which provides a quick onset of action and thereby 
help in treatment of allergic disorders. 
MATERIALS AND METHODS 
Materials 
Chlorpheniramine maleate (CPM) was procured as a gift sample from 
Cadila Pharmaceuticals Ltd., Ahmedabad. Tartaric acid, fumaric acid, 
sodium bicarbonate, lactose, sodium benzoate, and sucrose were 
procured from Merck India Ltd., Mumbai, India. Polyvinyl pyrroledone 
(PVP) was purchased from Sigma Aldrich, India. All other ingredients 
and chemicals used in the study were of analytical grade.  
Preparation of effervescent tablets 
Tartaric acid, fumaric acid, sodium bicarbonate, lactose and sucrose 
were weight and transferred in double cone mixture (Kalweka, 
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Karnavati Engineering Ltd., India) for 15 min and then passes through a 
sieve 40#. The powder was compressed to prepare tablets (8 mm 
diameter) using a rotary tablet compression machine (RIMEK Mini Press 
II, Make: Karnavati after Engineering, Ltd. India) [9]. Developed tablets 
were evaluated for different evaluation parameter as per IP [10]. 
Experimental design 
To study the effect of factors, identified during preliminary trials, on 
the various properties of effervescent tablets, experiments were 
systematically conducted by employing box behnken design. Design 
Expert® software (trial version 7.1.2, Stat-Ease, Inc., Minneapolis, 
MN) was used to graphically express the influence of each factor on 
the response by generating the response surface plots [11]. The 
amount of sodium bicarbonate (X1), amount of tartaric acid (X2) and 
amount of fumaric acid (X3
Y
) were selected as independent variables. 
The dependent response variables measured were disintegration 
time, amount of carbon dioxide and % drug release after 5 min. The 
composition of design batches is shown in table 1 and levels of 
independent variables in coded as well as in actual form is shown in 




i  is the dependent variable; b0 is the intercept; b1, b2, b3, 
b12, b23, b13 are the regression coefficients; and X1, X2 and X3
 
 are the 
independent variables. All the batches were prepared and evaluated 
in triplicate (n=3). 
Table 1: Composition of effervescent tablets of CPM 
Ingredients  B1 B2 B3 B4 B5 B6 B7 B8 B9 B10 B11 B12 B13 B14 B15 B16 B17 
CPM 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 
Sodium 
Bicarbonate 
125 125 125 150 125 125 100 125 125 150 125 150 100 125 100 100 125 
Tartaric acid 30 40 30 40 30 30 30 30 20 20 20 30 30 40 40 20 30 
Fumaric acid 30 20 30 30 30 30 40 30 20 30 40 20 20 40 30 30 40 
Sucrose 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 
Sodium  
Benzoate 
10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 
Polyvinyl- 
pyrrolidone 
6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 
Lactose 65 65 65 30 65 65 80 65 85 50 65 50 100 45 80 100 55 
 Total 300 300 300 300 300 300 300 300 300 300 300 300 300 300 300 300 300 
All the quantities are in mg. 
 
Table 2: Variables and their levels in box-behnken design 
  Levels  
Independent variables Low Medium High 
X1 100 = amount of sodium bicarbonate (mg) 125 150 
X2 20 = amount of tartaric acid (mg) 30 40 
X3 20 = amount of fumaric acid (mg) 30 40 




= disintegration time (sec) 
2
Y
=amount of carbone dioxide (gm) 
3= Drug release after 5 min (%) 
 
Selection of optimized formulation was done after considering the 
results of dependent variables of the experimental design batches. 
The batch with lower disintegration time and higher carbon dioxide 
and drug release in 5 minutes will be considered as optimized batch. 
The selected dependent variables are correlated with each other 
because the higher amount of released carbon dioxide results in 
faster bursting of tablets and hence lower disintegration time and 
faster drug release property. 
Evaluation of tablet 
Post compression evaluation of tablet  
Weight variation study of the tablets was performed by accurately 
weighing the 10 tablets individually using digital weighing balance 
and calculated the average weight of the tablets. Individual weights 
of tablets were compared with the average weight of the tablets 
[10]. Hardness of the tablet was studied using hardness tester (DHT-
250, Cambell Electronics Machine, Thermonik) by calculating the 
force required to split a tablet by compression in the diametric 
direction. Same instrument was used to measure diameter and 
thickness of tablets. Friability was measured using Roche friabilator 
USP at 25 rpm for 4 min [12-14]. 
Disintegration study 
The tablet disintegration time was measured as per pharmacopoeial 
procedure. The beaker of 250 ml was filled with 200 ml of water and 
one tablet was added in the beaker. The time required for a tablet to 
disintegrate was determined using visual observation [12-14]. 
Amount of carbon dioxide 
The amount of carbon dioxide was measured by the method 
developed by G. Rajalakshmi et al. 10% sulfuric acid solution was 
prepared in distilled water. 100 ml of prepared sulfuric acid solution 
was taken in a beaker of 250 ml and weight of beaker was taken. 
One tablet was added in a beaker and tablet was observed for 
complete release of carbon dioxide from the tablet. Again weight of 
the beaker was determined and the difference in weight before and 
after release of carbon dioxide shows the amount of carbon dioxide 
generated [15, 16]. 
In vitro dissolution 
The dissolution study was executed in 500 ml of 0.01 M HCl buffer 
media at 37oC ± 2oC using USP apparatus II (TDT08L, Dissolution 
Tester (USP), Electrolab) at 50 rpm. Samples were withdrawn at 
time intervals of 5, 15, 30, 45, 60, 90, 120 min. The same amount of 
fresh dissolution medium was replaced after withdrawal of the 
sample. Drug content was analyzed at 264 nm by UV double beam 
spectrophotometer (UV 1800 Shimadzu Scientific Instrument, 
Japan). The cumulative percent of drug released was calculated 
using a calibration equation generated from the standard curve and 
plotted as percent cumulative drug released versus time [10]. 
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In vivo study 
The in vivo pharmacokinetic study was carried out on the rabbit 
animal model (Protocol No: RPCP/IAEC/2013-2014/R-28). In vivo 
pharmacokinetic study was performed by dividing the animals in 2 
groups (n=6). Animals were fasted over night and were placed in a 
restraining device (rabbit holder) before administration of reference 
(drug suspension in water) and test (optimized batch) formulations. 
Formulations were administered using a feeding needle. Blood 
samples were collected from a marginal ear vein and collected with 
the help of a syringe attached to a hypodermic needle. For smooth 
blood collection, syringe was removed from the needle and cannula 
was closed to prevent blood clotting. The cannula was flushed with 
sodium citrate solution before closing to prevent blood clotting. 1 ml of 
blood was withdrawn at following time interval of 30, 60, 90,1210,150 
and 180 min through the cannula into 2 ml micro centrifuge tubes 
which contain 0.5 ml of sodium citrate solution [17]. 
Chromatographic conditions 
Reversed phase HPLC method was used to estimate CPM in plasma 
samples using sensitive and validated Shimadzu LC-20AT HPLC 
system with SPD-20A detector (Shimadzu). The CPM was analyzed 
at 262 nm using UV-Visible detector. Methanol: phosphate buffer 
(pH 2.8) as a ratio of 60:40 was used as mobile phase and was 
filtered and degassed before use. The mobile phase was pumped at 1 
ml/min flow rate [18]. 
Estimation of CPM in blood sample  
Plasma aliquots of 0.5 ml was taken from rabbit plasma for 
analysis of CPM and transferred into a 2-mL centrifuge tube. In 
the same centrifuge tube, 1.5 ml of methanol was added and 
vortexes using a vortex mixer for 10 min at 3,000 rpm. After 
centrifugation, organic layer was separated and evaporated at 37 
°C to get dry residue. 250 μl of mobile phase was added to 
dissolve the residue and from that 20μl was injected for 
estimation of drug content. 
RESULTS AND DISCUSSION  
Post compression evaluation of tablet  
The results of weight variation study, shown in table 3, were not 
showing a significant difference in the weight of individual tablet 
from the average value. Average diameter and thickness of the 
tablets were mentioned in table 3. The diameter was found in the 
range of 7.44±0.014 mm to7.89±0.009 mm and the thickness was 
between 3.30±0.012 mm to 3.95±0.008 mm.  
The hardness and friability were shown in table 3 for all the 
formulation. Hardness was found in a range of 1.16±0.016 kg/cm2 to 
3.94±0.008 kg/cm2 
 
where as friability was found in a range of 
0.45±0.010 % to 0.68±0.009% which is (that is less than 1%) in the 
acceptable limit. 
Table 3: Post compression evaluation of design batches 









, n=5) (%, n=5) 
Drug content 
(%, n=5) 
B1 301.00±0.82 3.87±0.017 7.77±0.09 2.86±0.012 0.68±0.009 100.42±0.289 
B2 293.33±1.25 3.36±0.009 7.76±0.016 2.06±0.016 0.67±003 99.67±0.173 
B3 301.00±0.82 3.34±0.017 7.87±0.019 2.57±0.029 0.66±0.019 98.75±0.346 
B4 301.33±0.94 3.95±0.008 7.84±0.009 1.76±0.009 0.67±0.004 99.97±0.577 
B5 298.67±0.47 3.44±0.012 7.44±0.014 2.85±0.029 0.66±0.010 100.75±0.173 
B6 305.67±0.94 3.56±0.016 7.75±0.005 3.64±0.026 0.45±0.012 98.75±0.115 
B7 300.67±0.94 3.32±0.012 7.75±0.009 1.95±0.022 0.45±0.316 100.33±0.231 
B8 302.67±0.47 3.45±0.021 7.76±0.014 3.94±0.008 0.66±0.216 99.42±0.289 
B9 297.67±0.47 3.55±0.014 7.84±0.009 2.16±0.012 0.66±0.008 100.75±0.115 
B10 298.67±1.25 3.73±0.017 7.99±0.05 3.72±0.022 0.66±0.014 98.67±0.577 
B11 300.33±0.47 3.59±0.012 7.77±0.00 1.30±0.012 0.66±0.017 98.42±0.321 
B12 301.67±0.47 3.30±0.012 7.74±0.019 2.53±0.021 0.45±0.010 101.00±0.251 
B13 302.33±1.25 3.46±0.012 7.74±0.009 2.65±0.012 0.45±0.316 99.83±0.404 
B14 298.00±0.82 3.56±0.009 7.84±0.019 1.16±0.016 0.66±0.008 99.67±0.252 
B15 301.67±0.47 3.42±0.019 7.89±0.005 2.16±0.012 0.67±0.004 99.42±0.451 
B16 303.00±0.82 3.44±0.008 7.89±0.009 1.66±0.017 0.64±0.024 101.08±0.090 
B17 295.33±0.47 3.44±0.012 7.86±0.026 2.86±0.012 0.62±0.014 100.17±0.755 
Table 4: Formulation of effervescent tablets using box-behnkendesign 
Batch 
code 
X X1 X2 Y3 1 
(sec, n=3) 
(Disintegration time) Y2 
(g, n=3) 
(amount of carbon dioxide) Y3 
(%,n=3) 
(Drug release after 5 min) 
B1 -1 -1 0 143.66±0.603 0.27±0.072 94.3±0.398 
B2 1 -1 0 150±0.998 0.33±0.062 97.06±0.875 
B3 -1 1 0 103.33±0.236 0.27±0.053 95.4±0.577 
B4 1 1 0 119.83±0.747 1.26±0.077 97.49±0.407 
B5 -1 0 -1 148.5±0.292 0.81±0.24 95.39±0.416 
B6 1 0 -1 142.66±0.490 0.34±0.068 97.19±0.458 
B7 -1 0 1 145±0.399 0.26±0.014 96.06±0.529 
B8 1 0 1 126.17±0.514 0.27±0.019 97.31±0.522 
B9 0 -1 -1 157±0.748 0.27±0.025 92.05±0.665 
B10 0 1 -1 145.17±0.564 1.1±0.021 94.82±0.769 
B11 0 -1 1 146.83±0.608 0.27±0.058 95.02±0.589 
B12 0 1 1 119.04±0.441 1.75±0.058 96.82±0.346 
B13 0 0 0 124.33±0.625 2.03±0.056 95.231±0.513 
B14 0 0 0 121.89±0.558 1.96±0.068 93.93±0.643 
B15 0 0 0 123.83±0.517 1.91±0.035 94.23±0.658 
B16 0 0 0 123.33±0.522 1.96±0.092 93.93±0.520 
B17 0 0 0 122.17±0.847 1.83±0.040 95.92±0.501 
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Data analysis  
Results of experimental design batches (B1 to B17) were shown in 
table 4. Box-Behnken design was used to optimize the amount of 
sodium bicarbonate, tartaric acid and fumaric acid to get the faster 
disintegration time and a higher amount of carbon dioxide and drug 
release after 5 min. The results of statistical analysis for design 
batches were obtained by Design Expert® software and were shown 
in table 4. The polynomial equation generated for each response by 
software was described in equation 1-3 and response surface plot 
for each response was shown in fig. (1-3). 
Effect of disintegration time 
The disintegration time ranged from 103.33±0.24 sec to 
157.00±0.75 sec for all the formulations.  
Disintegration time (Y1) = 123.111-0.23*X1-13.76*X2-7.04*X3+ 2.54* 
X1X2-3.25X1X3-3.99* X2 X3+2.33X12+3.76X22+15.14 X3 2
The polynomial equation depicts that the magnitude of coefficient of 
X
(1) 
1, X2 and X3 shows the negative effect which means that as the 
amount of all the three parameters increased, disintegration time is 
decreased. This might be due to faster formation of carbon dioxide 
because of the higher amount of these ingredients. X2 and X3 
 
had 
shown a significant effect on the (p<0.05, table 5) disintegration time. 
The overall model was significant because the p value was<0.05. 
Similar results can be seen in the 3D surface plots (fig. (1)). Similar 
types of results were observed by Jacob et al. [14] while developing 
effervescent tablets of Glibenclamide. They observed that as the 
amount of disintegrating agent (sodium carbonate and acids) 
increased in the formulation, disintegration of tablets become fast.
 
Fig. 1: 3D Surface plot for disintegration time 
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Table 5: Results of p value and regression coefficient 
  p values of coefficients  
Responses b b0 b1 b2 b3 b12 b13 b23 1 b2 2 b2 3 R2 2 
Disintegration time 0.0169 0.9372 0.0017 0.0402 0.5417 0.4392 0.3472 0.5645 0.3622 0.0057 0.8775 
Amount of carbon dioxide 0.0045 0.5433 0.0099 0.9750 0.1975 0.4863 0.3528 0.0007 0.0180 0.0069 0.9188 
Drug release in 5 min 0.0698 0.0261 0.0666 0.0796 0.7459 0.7900 0.6404 0.0126 0.6948 0.6536 0.8043 
 
Amount of carbon dioxide 
The amount of carbon dioxide ranged from 0.26 ± 0.014 gm to 
2.03±0.056 gm for all the formulations B1 to B17.  
Amount of CO2 (Y2) = 1.94+0.074*X1+0.41*X2+3.750E-
003*X3+0.23* X1 X2+0.12* X1 X3+0.16* X2 X3-0.92X12-0.49X22-
0.60X32
The polynomial equation depicts that the magnitude of coefficient of 
X
(2) 
1, X2 and X3 shows positive effect and X2 had a significant effect 
(p<0.05, table 5) on the amount of carbon dioxide. The overall model 
was significant because the p value was<0.05. The coefficient value of 
X1, X2 and X3 were nearly similar. The values of interactive term for X1, 
X2 and X3
 
Fig. 2: 3D Surface plot for amount of carbon dioxide 
 were positive. From the 3D surface plot, as showed in fig. (2), it 
can also be concluded that the amount of carbon dioxide increases with 
increase in the amount of sodium bicarbonate, tartaric acid and fumaric 
acid. Similar type of results were obtained by Amela et al. [16] and Yanze 
et al. [19] while developing the effervescent formulation containing citric 
acid and sodium bicarbonate. 
 
 
Drug release after 5 min 
Drug release after 5 min was obtained from92.05 ± 0.67% to 97.49 ± 
0.41% for all the formulations B1 to B17.  
Drug release after 5 min. (Y3) = 94.65+0.99*X1+0.76* X2+0.72* X3-
0.17* X1 X2-0.14* X1 X3-0.24* X2 X3+1.61X12-0.20X2 2+0.23X3 2
The polynomial equation depicts that the magnitude of coefficient of 
X
(3) 
1, X2 and X3 shows positive effect and X1 had shown a significant 
effect (p<0.05, table 5) on drug release after 5 min. 3D surface plots 
(fig. (3)) suggested that the higher amount of tartaric acid, fumaric 
acid and sodium bicarbonate gave faster drug release. All the 
batches were showing more than 90% drug releases after 5 
minutes. Drug release profile of the design batches is shown in fig. 
(4). Tekade et al. [20] made the effervescent tablet of diclofenac 
sodium using the sodium bicarbonate with citric acid was showing 
drug release. Use of two acid sources may be the reason for faster 
drug release. 
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Fig. 3: 3D surface plot for drug release after 5 min 
 
 
Fig. 4: Drug release of design batches 
 
From the results of design batches, batch B4 was selected as 
optimized batch due to higher amount of released carbon dioxide 
and faster drug release as compared to other batches. Disintegration 
time, amount of release carbon dioxide and drug release in 5 
minutes for batch B4 were 119.83 ± 0.78 sec, 1.26 ± 0.58 and 97.49 ± 
0.41% respectively. This batch was further subjected to in vivo study 
using a rabbit model. 
In vivo study 
Standard solution of CPM was prepared in the mobile phase of 
methanol: phosphate buffer (pH6.8) with a ratio of 60:40. Different 
dilutions were made and 20 µl was injected to HPLC system. Same 
process was done in triplicate to measure the reproducibility of 
results. The results showed good correlation between the 
concentration of CPM and peak area, and linear relationships in 
plasma concentration ranging from 500 ng/ml. to 5500 ng/ml. The 
method used for analysis was reproducible with good precision 
which can be concluded from its percentage accuracy for intra-day 
and inter-day studied batches and was complied with the limit of 85-
115%. 
The maximum plasma concentration (Cmax), time to reach the 
maximum plasma concentration (tmax), area under the drug plasma 
concentration-time curve up to 2 h post-administration (AUC 0-2 h) 
and the elimination half-life (t1/2) was calculating using non 
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compartmental analysis and are shown in table 6. From the fig.(5), 
tmax
Parameter 
 was higher in case of effervescent tablet solution of batch B4 
compared to drug suspension. 
 
Table 6: Pharmacokinetics parameters of reference and 
optimized batch formulations 
Reference Optimized batch (B4) 
AUC (0-180 min) 71.4 73.86 
tmax 90 (min) 60 
Cmax 2.74 (ng/ml) 2.76 
 
 
Fig. 5: Drug release in rabbit plasma 
 
CONCLUSION 
The study concluded that the combination of sodium bicarbonate, 
tartaric acid and fumaric acid approach for development of 
effervescent tablet aids to achieve faster disintegration and faster drug 
release property for CPM. The Box-Behnken design was employed for 
the optimization and studies the effect of process parameters and their 
interaction on the effervescent formulation. Optimized batch B4 was 
showing higher amount of released carbon dioxide and faster drug 
release as compared to other batches. Batch B4 was also showing a 
higher AUC and Cmax while lower tmax
1. Hassan HE, Aboloyoun AI. The value of bedside tests in 
dysphagia evaluation. Egyptian J Ear Nose Throat Allied Sci 
2014;15(3):197–203. 
 as compared to drug suspension 
while performing in vivo study of optimized batch in rabbit model. 
Thus, it could be concluded that the combination of acids and sodium 
bicarbonate helps to develop effervescent tablets. Use of experimental 
design might be helpful to develop effervescent formulation with 
desired characteristics like faster disintegration and drug release with 
minimum efforts in the shortest time. 
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